摘要
目的观察乳腺癌新辅助化疗前后雌激素受体(ER)、孕激素受体(PR)、人v-erb-B-2相关基因(c-erb-B-2)、P53基因(P53)、Ki67抗原(Ki67)表达的改变及意义以及与化疗疗效的关系。方法收集35例乳腺癌患者,新辅助化疗(NAC)采用紫杉类联合蒽环类方案4~6疗程后进行临床疗效评价;对比化疗前后ER、PR、c-erb-B-2、P53、Ki67变化以及与化疗疗效的关系。结果临床总有效率为91.42%,临床获益率(cCR+cPR+SD)为100.00%。NAC前后Ki67状态有12例发生变化,差异有统计学意义(P<0.05)。Ki67数值有31例发生变化,Ki67数值在有效组、无效组分别有27例、1例降低,差异有统计学意义(P<0.05)。结论NAC对ER、PR、c-erb-B-2、P53的状态无显著影响,而显著降低Ki67表达,Ki67可预测乳腺癌新辅助化疗的疗效。
Objective To observe the immunohistochemical changes and significance of breast cancer after neoadjuvant chemothera-py,and to explore the relationship between ER,PR,c-erb-B-2,P53,Ki67 expression and chemotherapeutic effect.Methods Thirty-five cases of breast cancer patients were treated by neoadjuvant chemotherapy,which was taxanes and anthracyclines scheme for 4~6 cycles.Clinical e-valuation of the effect of neoadjuvant chemotherapy was done after the treatment.The relationship between ER,PR,c-erb-B-2,P53,Ki67 chan-ges and immuno-histochemical results with chemotherapeutic effect was contrasted before and after chemotherapy.Results The total effective rate was 91 .42%,and the clinical benefit rate was 1 00.00% (cCR+cPR+SD).After neoadjuvant chemotherapy,Ki67 changed in 31 pa-tients,which was statistically significant(P<0.05).The value of Ki67 in the effective group and invalid group was decreased in 27 cases and 1 case,respectively,and the difference was statistically significant(P<0.05).Conclusion Neoadjuvant chemotherapy has no significant in-fluence on ER,PR,c-erb-B-2,P53,but it can significantly decrease Ki67 expression.Ki67 can predict the effect of neoadjuvant chemotherapy for breast cancer.
出处
《安徽医学》
2014年第6期724-726,共3页
Anhui Medical Journal
基金
北京市东城区卫生局2008年科研项目(项目编号:东卫[科]3589)
关键词
乳腺癌
新辅助化疗
雌激素受体
KI67抗原
Breast cancer
Neoadjuvant chemotherapy
Estrogen receptor
Ki67antigen
